Cancer diagnosis can often be an exhausting, extensive process with endless tests, scans, and screenings. We all know the importance of early detection and successful treatments to potentially save thousands of lives every year, so could liquid biopsies offer the lifeline we’ve been holding out for?
There is no denying the presence of computers in our everyday life, whether it’s through phones, personal virtual assistants such as Apple’s Siri and Amazon’s Alexa, or video games. Lately, the interest and development surrounding artificial intelligence (AI) has escalated, and the opportunities to embrace this within the healthcare industry seem to be growing.
Here in the United Kingdom, we have the worst survival rates for brain cancer in Europe, with just 14% of patients surviving for ten or more years. Whilst prognosis for most other types of cancer has improved, brain tumour survival rates have remained stagnant, with no game-changing new drugs being developed in the last fifty years. As brain tumours progress, the aggressive nature of the disease becomes apparent.
This year on the 8th March, World Kidney Day coincided with International Women’s Day. With chronic kidney disease affecting 195 million women worldwide, the chosen theme ‘Kidneys & Women’s Health: Include, Value, Empower’ only feels apt. Despite playing a vital role in the body maintaining homeostasis, kidney health is often overlooked by many of us, and if neglected could lead to serious health implications for both men and women.
World Cancer Day is on the 4th of February. The purpose is to increase global awareness and get as many people talking about the disease as possible. Essentially, unite people from all around the world in the fight against cancer—and with worldwide incidence set to increase to 21.7 million by 2030, the fight is now. 2018 is the last in the three year ‘We Can. I can.’ campaign
In November last year, after much debate over cost, the National Institute for Health and Care Excellence (NICE) approved two new drugs for treatment of breast cancer for use on the NHS. Although first approval happened some time ago, this decision to make palbociclib and ribociclib available on the NHS, gives thousands more people access.